

Know Now. Not Later.

Genetic Risk Assessment

For Opioid Use Disorder (OUD)

AvertD
Designed by SOLVD HEALTH

Do. No. Harm.

Treating acute pain—pain expected to last <30 days—safely and effectively is a priority for both providers and patients. But when a first prescription of oral opioids is being considered, it's important to understand that the risk of opioid addiction is higher for some patients than others. AvertD can help identify these patients before a prescription is written.

What is AvertD?

AvertD is a clinically validated genetic test that helps patients and their doctors better understand their genetic risk for developing Opioid Use Disorder (OUD), also known as opioid addiction. When a first prescription of oral opioids is being considered to treat acute pain, AvertD provides personalized genetic risk information for OUD to physicians and their patients to support more informed decision-making about acute pain management.

When should AvertD be used?

AvertD is a physician-ordered test intended for use prior to a first prescription of oral opioids to treat acute pain. AvertD test results provide personalized genetic risk information for OUD to support more informed decision-making when short-term use of prescription oral opioids is being considered, such as after elective surgeries like orthopedic surgery and dental procedures.

Because genetics is only one of many known factors associated with increased risk for OUD, AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of prescription oral opioids for acute pain management.

How does AvertD work?

Using a simple cheek swab sample, AvertD analyzes 15 genetic markers involved in the brain reward pathways associated with addiction to identify if a patient may be at increased genetic risk for OUD. The AvertD result report will identify whether the patient has a High Genetic Risk or a Low Genetic Risk. This report will be made available to the ordering healthcare provider via a secure online portal after the cheek swab is received and processed at our CLIA-certified, CAP-accredited lab.

Be Informed.

AvertD was clinically validated through a blinded, multi-center, longitudinal study evaluating patients after their initial exposure to prescription oral opioids for 4 to 30 days (n=385). They were evaluated at least one year post-exposure. The study design allowed for random representative sampling mirroring adults in the U.S. prescribed oral opioids.

How accurate is the test?

In the published clinical validation study, AvertD demonstrated 82% sensitivity and 80% specificity. There were no statistically significant differences in clinical performance observed based on gender, age, length of follow-up from opioid exposure, race, or ethnicity.

What do the results mean?

AvertD test results should always be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in an acute pain management plan. Non-genetic factors contribute to the likelihood of OUD and must also be considered when evaluating the appropriateness of opioid therapy.

High Genetic Risk: Based on the clinical validation study, patients with a High Genetic Risk are 16x more likely to develop OUD than patients with a Low Genetic Risk.* If a patient is identified as having a High Genetic Risk, alternative pain management options may be explored in order to minimize or avoid use of opioids.

Low Genetic Risk: Based on the clinical validation study, patients with a Low Genetic Risk are 16x less likely to develop OUD than patients with a High Genetic Risk.* If a patient is identified as having a Low Genetic Risk, existing federal, state, and medical specialty guidelines should still be followed to ensure safe and effective opioid prescribing.

**Based on an OUD prevalence of 5% in the post-surgical population*

Source: Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460

How much does the test cost?

Our goal is to offer patients the lowest cost option available to them. We are working diligently to ensure AvertD is covered by most insurance companies. Depending on the patient's insurance, their maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on behalf of the patient. For details about coverage, please contact the patient's insurance company. If the patient's insurance does not pay for the test, the patient will be billed directly for $199.

Learn more at AvertDTest.com.

Designed for Change.
Designed for Health.
Designed for Peace of Mind.

1-760-598-1223 | customerservice@solvdhealth.com | solvdhealth.com

Testing performed by Prescient Lab Services on behalf of SOLVD Health
1600 Faraday Ave, Suite 200, Carlsbad, CA 92008 USA
CLIA: 05D2051580 CAP: 7196892 CA License: CDF 00343474